Oral administration of PDX1 confers protection against insulitis in the non-obese diabetic (NOD) mice
Oral administration of PDX1 confers protection against insulitis in the non-obese diabetic (NOD) mice
复制标题
口服 PDX1 可预防非肥胖糖尿病 (NOD) 小鼠的胰岛素炎
DOI：
10.1016/j.bbrc.2015.09.098
复制
发表时间：
2015-10-30
影响因子：
3.1
通讯作者：
Chen, Li
中科院分区：
文献类型：
--
作者：
Lin, Peng;Li, Wenjuan;Chen, Li
1型糖尿病是一种T细胞介导的器官特异性自身免疫性疾病。抗原特异性免疫干预允许选择性靶向自身反应性T细胞，同时使免疫系统的其余部分保持完整。然而，1型糖尿病的免疫干预在临床上并没有取得理想的效果。在我们之前发表的论文中，我们询问胰腺十二指肠家庭盒1（PDX 1）是否是1型糖尿病抗胰岛自身免疫的靶点。在本实验中，我们评估了口服PDX 1对4周龄非肥胖糖尿病（NOD）小鼠的糖尿病发展的治疗效果。结果表明，PDX 1免疫是一种有效的干预策略，用于延迟NOD小鼠糖尿病的发作，与以下因素相关：1）减少胰岛炎; 2）抑制破坏性自身反应性T细胞; 3）增加调节性T细胞; 4）细胞因子产生的转变。目前的观察结果表明，用PDX 1免疫调节NOD小鼠的免疫细胞应答，提高了它有益于改善β细胞的自身免疫破坏和延迟I型糖尿病临床发展的可能性。(C)2015爱思唯尔公司All rights reserved.
Type 1 diabetes is a T cell-mediated organ-specific autoimmune disease. Antigen-specific immune intervention allows the selective targeting of autoreactive T cell, while leaving the remainder of the immune system intact. However, immune intervention for type 1 diabetes has not yielded perfect results clinically. In our paper published previously, we asked whether pancreatic duodenal home box 1 (PDX1) is a target of anti-islet autoimmunity in type 1 diabetes. In this experiment, we assessed the therapeutic effect of oral administration of PDX1 on diabetes development of 4-week-old non-obese diabetic (NOD) mice. The results indicate that PDX1 immunization is an effective intervention strategy for delaying the onset of diabetes in NOD mice in association with: 1) reduced insulitis; 2) suppression of destructive autoreactive T cells; 3) augmentation of regulatory T cells; 4) a shift in cytokine production. The present observations suggest that immunization with PDX1 modulates immune cell responses in NOD mice, raising the possibility that it is beneficial in ameliorating autoimmune destruction of beta-cells and delaying type I diabetes development clinically. (C) 2015 Elsevier Inc. All rights reserved.